1993
DOI: 10.1378/chest.104.1.203
|View full text |Cite
|
Sign up to set email alerts
|

A Comparison of Chemotherapy and Radiotherapy as Adjuvant Treatment to Surgery for Esophageal Carcinoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

1997
1997
2021
2021

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 59 publications
(4 citation statements)
references
References 6 publications
0
4
0
Order By: Relevance
“…12 Postoperative adjuvant chemotherapy was administered to all eligible patients according to the protocols of the Japan Esophageal Oncology Group, which conducted three consecutive randomized controlled trials after 1980. [5][6][7] Preoperative adjuvant therapy was administered as follows: one patient received chemotherapy, 95 patients received radiation therapy, and 27 patients received chemoradiation therapy. Postoperative adjuvant therapy was administered as follows: 19 patients received radiation therapy and 21 patients received chemotherapy.…”
Section: Preoperative Staging Techniquesmentioning
confidence: 99%
See 1 more Smart Citation
“…12 Postoperative adjuvant chemotherapy was administered to all eligible patients according to the protocols of the Japan Esophageal Oncology Group, which conducted three consecutive randomized controlled trials after 1980. [5][6][7] Preoperative adjuvant therapy was administered as follows: one patient received chemotherapy, 95 patients received radiation therapy, and 27 patients received chemoradiation therapy. Postoperative adjuvant therapy was administered as follows: 19 patients received radiation therapy and 21 patients received chemotherapy.…”
Section: Preoperative Staging Techniquesmentioning
confidence: 99%
“…1 In Japan, three-field lymph node dissection (3FLD), 2,3 i.e., neck, mediastinal, and abdominal lymphadenectomy, has been introduced to improve the long-term survival of such patients through 1980s. Nevertheless, despite improved surgical techniques 4 and adjuvant therapy, [5][6][7] early recurrence is still frequently observed in patients with upper thoracic tumors. 8 Because only a few reports have analyzed the distribution of positive lymph nodes and prognostic factors for patients with upper thoracic esophageal carcinoma, [8][9][10] it is still unclear which patients should be treated with cervical lymph node dissection.…”
Section: Introductionmentioning
confidence: 99%
“…-S vs S-ACRT vs S 238 SCC thoracic esophagus 40Gy/2Gy/20f two cycles PTX 135mg/m 2 /d + DDP 20 mg/m 2 /d d1-3, 22-24 Ancona et al (12) NCT-S vs S 94 SCC esophagus NA two cycles cisplatin 100mg/m 2 d1, 21 + 5-fluorouracil 1000mg/m 2 d1-5, 21-26 Nygaard et al (27) S vs NCT-S vs NRT-S vs NCRT-S 186 SCC located at least 21 cm from the incisor teeth, or below the 5th thoracic vertebra 35Gy/1.75Gy/20f two cycles cisplatin 20mg/m 2 d1-5 + bleomycin 5mg/m 2 d1 Allum et al (11) NCT-S vs S 802 AC, SCC, undifferentiated carcinoma esophagus or GEJ NA two cycles cisplatin 80mg/m 2 d1 + fluorouracil 1000 mg/m 2 daily as a continuous infusion over 96 hours q3w Boonstra et al (16) NCT-S vs S 169 SCC thoracic esophagus NA two-four cycles cisplatin 80mg/m 2 d1, etoposide 100 mg/m 2 d1,2, followed by etoposide 200mg/m 2 orally d3,5 q3w Bosset et al (17)NCRT-S vs S 282 SCC thoracic esophagus 37Gy/3.7Gy/10f two cycles cisplatin 80mg/m 2 , d1-3 Burmeister et al(18) NCRT-S vs S 256 AC, SCC thoracic esophagus 35Gy/2.3Gy/15f one cycle cisplatin 80mg/m 2 d1+ fluorouracil 800mg/m 2 d1-4Ando et al(14) S-ACT vs S 205 SCC thoracic esophagus NA two cycles cisplatin 70mg/m 2 + vindesine 3mg/m 2 d1, 21 Ando et al(15) S-ACT vs NCT-S 330 SCC thoracic esophagus NA two cycles cisplatin 80mg/m 2 d1+ 5-fluorouracil 800mg/m 2 d1-5 Ando et al(13) S-ACT vs S 242 SCC thoracic esophagus NA two cycles cisplatin 80mg/m 2 d1 + fluorouracil 800mg/m 2 d1-5 Jeog(21) S-ART vs S-ACT 258 NA cervical and thoracic esophagus 50Gy/2Gy/25f three cycles cisplatin 50mg/m 2 + vindesine 3mg/m 2 d1 Kelsen et al(22) NCT-S vs S 243 AC, SCC esophagus or GEJ NA three cycles cisplatin 100mg/m 2 d1 + 5-fluorouracil 100mg/m 2 d1-5 Burmeister et al(19) NCT-S vs NCRT-S 75 AC esophagus or GEJ 35Gy/2.3Gy/15f two cycles cisplatin 80mg/m 2 d1 + 5-fluorouracil 1000mg/m 2 /d d1-5 q3w…”
mentioning
confidence: 99%
“…Adelstein DJ et al [16] reported that the 4-year overall survival in resected esophageal cancer patients with a pathologic stage of T3, N1, or M1a receiving concurrent chemoradiotherapy is 51%, distant metastatic control is 56%, and locoregional control is 86%. The Japanese Esophageal Oncology Group [17] reported that there was no significant difference in survival up to 5 years in 2 groups that were treated with chemotherapy or radiotherapy after surgery. The reason that there was no significant difference in survival up to 5 years in the 2 groups was that there was no difference in the distribution of the risk of locoregional recurrence and distant metastasis in the 2 groups.…”
Section: Discussionmentioning
confidence: 99%